Akebia Therapeutics Inc. Stock
Price
Target price
€1.12
€1.12
-5.620%
-0.067
-5.620%
€3.60
10.05.24 / Tradegate
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akebia Therapeutics Inc. Stock
Heavy losses for Akebia Therapeutics Inc. today as the stock fell by -€0.067 (-5.620%).
Currently there is a rather positive sentiment for Akebia Therapeutics Inc. with 8 Buy predictions and 3 Sell predictions.
With a target price of 3 € there is potential for a 168.1% increase which would mean more than doubling the current price of 1.12 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Akebia Therapeutics Inc. | -5.620% | -12.373% | -22.668% | 19.807% | -4.522% | -53.375% | - |
Ardelyx Inc. | -3.860% | -10.646% | 8.770% | 81.814% | 24.879% | 33.667% | - |
Evolus Inc | -1.650% | -3.252% | 1.709% | 39.181% | 31.492% | 59.732% | - |
Salarius Pharmaceuticals Inc. | 2.480% | -8.811% | 2.985% | -70.216% | -25.405% | -98.392% | -99.993% |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The